Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Hematopoietic Stem Suppliers In Usa
19 companies found
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inAllendale, NEW JERSEY (USA)
We are a leading global contract development and manufacturing organization (CDMO) dedicated to the advancement and manufacturing of gene and cell therapy products. Minaris Regenerative Medicine is a leading global contract development and ...
based inSugar Land, TEXAS (USA)
Our mission is to develop and deliver adult stem cell solutions that are safe, effective and affordable for incurable conditions. Our vision is a world where stem cells are regularly used to not only treat disease but prevent it. Today, medicine is ...
The truth is that almost everyone that has banked their newborn's stem cells has banked for the purpose of banking rather than for the purpose of using. According to the American Society for Blood and Marrow Transplantation (ASBMT), the chance of a ...
based inFrederick, MARYLAND (USA)
In 2019, ProMedDx and GLAS Bio were acquired by Precision for Medicine, part of Precision Medicine Group. This new combination significantly bolstered the selection, scientific prowess and solutions available to customers from a single partner. With ...
Advancing your research into hematological malignancies, immunology, and other related areas requires access to high quality human bone marrow mononuclear cells. Precision for Medicine has an extensive inventory of normal, healthy donors with ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
based inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
based inSan Antonio, TEXAS (USA)
StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of ...
CELLvo™ Matrix is the only commercially available substrate that aims to recapitulate biochemical as well as structural and mechanical cues of the native niche by leaving the extracellular matrix intact. Cell-derived matrices create a ...
based inAlameda, CALIFORNIA (USA)
Since its inception in 1998, AllCells, a Discovery Life Sciences Company, has focused on advancing science in an innovative, collaborative, and client-centric manner. In our corporate video, AllCells’ Founder, Jay Tong, describes his early days in ...
Mobilized Leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate the migration of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow niche ...
based inMountain View, CALIFORNIA (USA)
Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to ...
CBM588 is an orally-administered Clostridium butyricum strain with a long history of clinical use and safety in all age groups in Japan. In Japan, CBM588 has primarily been used to treat infectious and noninfectious diarrheal disorders associated ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Trilaciclib (G1T28) hydrochloride is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological ...
based inSouth San Francisco, CALIFORNIA (USA)
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions. Our understanding of transplant patients and care teams allows us to develop solutions to extend graft life. With two decades of commitment to transplant ...
AlloSeq HCT can help you save time with a simple workflow and powerful analysis software, all while achieving high sensitivity chimerism monitoring. Engraftment monitoring (chimerism) testing evaluates the success of a hematopoietic ...
based inBeachwood, OHIO (USA)
We develop cell therapies - at a dramatically increased speed, at lower cost, and with less R&D risk. Trailhead Biosystems merges developmental biology and cell therapeutics with cutting-edge hardware and computerized experimental design and ...
We are developing human long-term hematopoietic stem cells (LT-HSCs) from human (non-embryo) induced pluripotent stem cells (iPSCs). HSCs are rare subsets of hematopoietic cells ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first ...
based inGrove City, OHIO (USA)
Forge is developing innovative gene therapies that aim to help patients suffering from devastating rare diseases. Forge is building capacity to directly address the growing demand for gene therapy manufacturing. Forge is currently building the ...
Krabbe disease is a devastating neurodegenerative disease affecting about 1 -2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase ...
based inCranbury, NEW JERSEY (USA)
Advancing an integrated pipeline of genetic therapies that correct the root cause of complex and rare life-threatening childhood disorders. Our mission is to develop first-in-class and best-in-class, curative gene therapies for patients with ...
LAD-I is a rare genetic disorder affecting the immune system and is caused by a defect in the ITGB2 gene, leading to a deficiency in CD18. Due to this deficiency, white blood cells (primarily neutrophils) are unable to leave the bloodstream to go to ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered ...
based inCambridge, MASSACHUSETTS (USA)
Editas Medicine is a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around ...
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 consists of patient-derived CD34+ hematopoietic ...
based inSeattle, WASHINGTON (USA)
We believe we are entering a new era of medicine. The ability to modify genes and use cells as medicines provides new tools to meaningfully change the outcome of many human diseases. Early pioneers have made good progress, but most of what we can ...
Hemoglobinopathies: Sickle cell disease, ...